SeaStar Medical Holding Co. (NASDAQ:ICU) Sees Large Increase in Short Interest

SeaStar Medical Holding Co. (NASDAQ:ICU) saw a large growth in short interest in March. As of March 31st, there was short interest totalling 3,590,000 shares, a growth of 10.8% from the March 15th total of 3,240,000 shares. Currently, 6.8% of the shares of the company are sold short. Based on an average daily volume of 6,010,000 shares, the days-to-cover ratio is presently 0.6 days.

Hedge Funds Weigh In On SeaStar Medical

Institutional investors have recently bought and sold shares of the business. Geode Capital Management LLC bought a new stake in shares of SeaStar Medical during the fourth quarter worth $63,000. Two Sigma Securities LLC bought a new stake in shares of SeaStar Medical during the second quarter worth $29,000. Kestra Advisory Services LLC raised its position in shares of SeaStar Medical by 181.5% during the fourth quarter. Kestra Advisory Services LLC now owns 81,500 shares of the company’s stock worth $36,000 after acquiring an additional 52,550 shares during the last quarter. Vanguard Group Inc. bought a new stake in shares of SeaStar Medical during the fourth quarter worth $116,000. Finally, Hudson Bay Capital Management LP raised its position in shares of SeaStar Medical by 38.8% during the second quarter. Hudson Bay Capital Management LP now owns 346,972 shares of the company’s stock worth $178,000 after acquiring an additional 96,972 shares during the last quarter. Institutional investors own 1.69% of the company’s stock.

SeaStar Medical Stock Up 7.2 %

Shares of ICU stock opened at $0.71 on Wednesday. The stock’s fifty day simple moving average is $0.83 and its 200 day simple moving average is $0.69. SeaStar Medical has a one year low of $0.16 and a one year high of $2.50.

SeaStar Medical Company Profile

SeaStar Medical Holding Corporation, a medical device company, develops a platform therapy to reduce the consequences of hyperinflammation on vital organs in the United States. The company offers inflammatory response to fend off infections and repair damaged tissue in the body. It is also developing products in various therapeutic areas, including pediatric and adult acute kidney injury on CRRT; cardiorenal syndrome in congestive heart failure; myocardial stunning in end stage renal disease; and hepatorenal syndrome.